$2.3 Million in New Funding Focused on Novel Biomarkers and Treatments
The Alzheimer's Drug Discovery Foundation (ADDF) announces $2,315,881 in funding for three new research investments—demonstrating its focus to accelerate and advance the use of biomarkers and potential new...
Alpha-synuclein is a DNA binding protein that modulates DNA repair with implications for Lewy...
HumansHuman subject tissue was procured through the Oregon Alzheimer’s Disease Center (ADC) and OHSU Department of Pathology and affected subjects had established clinical and pathological diagnoses (Dementia with Lewy Bodies). Tissue use was approved...
Subscriber Information – Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association
The content on this site is intended for health professionals.
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.
Advertisements on...
Dr. Michela Gallagher Wins Alzheimer’s Drug Discovery Foundation’s Prestigious Goodes Prize
Dr. Michela Gallagher has been named the recipient of the 2018 Melvin R. Goodes Prize for Excellence in Alzheimer's Drug Discovery. The prize, awarded by the Alzheimer's Drug...
RPS25 is required for efficient RAN translation of C9orf72 and other neurodegenerative disease-associated nucleotide...
RPS25 is required for efficient RAN translation of C9orf72 and other neurodegenerative disease-associated nucleotide repeats
Read more...
Assessing cost-effectiveness of early intervention in Alzheimer’s disease: An open-source modeling framework
Jump to Section1. Introduction2. Methods 2.1. Model overview 2.2. Data 2.3. Predementia to dementia 2.4. AD dementia 2.5. Community versus institution (AD dementia states) 2.6. Mortality 2.7. Decision-analytic inputs3. Cost-effectiveness analysis: Early intervention in predementia4. Results5. Discussion6. ConclusionsSupplementary dataReferencesThe change in...
19th International Conference on Alzheimer’s Drug Discovery Highlights Multiple Approaches
Nearly 200 academic and industry researchers gathered this week to share updates on preclinical and clinical-stage Alzheimer's disease research at the 19th International Conference on Alzheimer's Drug Discovery....
Possible epigenetic regulatory effect of dysregulated circular RNAs in Alzheimer’s disease model
Overall expression profile of mRNA, miRNA, and circRNAAmong a total of 39,429 mRNAs analyzed, the number of differentially expressed mRNAs in the brain of 7 M Tg2576 mouse was 1,108 (up-regulated, 417; down-regulated, 691) and...
Bilingualism in Primary Progressive Aphasia: A Retrospective Study on Clinical and Language Characteristics
Background:
Primary progressive aphasia (PPA) is a neurodegenerative disorder characterized by progressive deterioration of language. Being rare, reports of PPA in multilingual individuals are scarce, despite more than half of the world population being...
18F-FDG PET, the early phases and the delivery rate of 18F-AV45 PET as proxies...
Jump to Section1. Introduction2. Methods 2.1. Study population 2.2. Image acquisition and analysis 2.3. Statistical analysis3. Results 3.1. Reference regions 3.2. Validation of SRTM2-based R1 3.3. Optimization of early time frame of eAV45 3.4. CBF proxies versus H2O PET 3.5. CBF versus...
